WO2009089324A1 - Compositions and methods for promoting patency of vascular grafts - Google Patents

Compositions and methods for promoting patency of vascular grafts Download PDF

Info

Publication number
WO2009089324A1
WO2009089324A1 PCT/US2009/030407 US2009030407W WO2009089324A1 WO 2009089324 A1 WO2009089324 A1 WO 2009089324A1 US 2009030407 W US2009030407 W US 2009030407W WO 2009089324 A1 WO2009089324 A1 WO 2009089324A1
Authority
WO
WIPO (PCT)
Prior art keywords
polymeric
vascular graft
conduit
poly
graft
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/030407
Other languages
English (en)
French (fr)
Inventor
Christopher Breuer
Themis Kryiakides
Jason Roh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Priority to JP2010542335A priority Critical patent/JP2011509156A/ja
Priority to US12/811,676 priority patent/US9855370B2/en
Publication of WO2009089324A1 publication Critical patent/WO2009089324A1/en
Anticipated expiration legal-status Critical
Priority to US15/850,364 priority patent/US20180193529A1/en
Priority to US17/713,766 priority patent/US12186455B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/507—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials for artificial blood vessels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
    • A61F2/06—Blood vessels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/426—Immunomodulating agents, i.e. cytokines, interleukins, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/602—Type of release, e.g. controlled, sustained, slow
    • A61L2300/604—Biodegradation

Definitions

  • Patent Application No. 61/010,406 filed on January 8, 2008. by Christopher K. Breuer, Themis R. Kyriakides and Jason D. Roh, and where permissible is incorporated by reference in its entirety.
  • Cardiac defects are the most common congenital anomalies affecting nearly 1% of all live births. Despite major advances in the treatment of congenital heart disease (CHD), it remains the leading cause of death due to congenital anomalies in the newborn period. CHD results from a myriad of structural anomalies that present over a broad spectrum. Single ventricle anomalies make up one of the largest groups of cardiac anomalies resulting in severe, life-threatening disease. Single ventricle anomalies are made up of a group of cardiac defects that are dramatically different from each other structurally, but share a common feature that only one of two ventricles is of adequate functional size.
  • the disclosed grafts are substantially tubular in shape with a round or substantially round cross section.
  • the tubular grafts have a lumen extending throughout the length of the graft.
  • the grafts may be of any appropriate length and diameter that is suitable for the intended surgical use of the graft. Typically, the graft should be slightly longer than the length of artery or vein that is to be replaced.
  • IL-IB interleukin-lbeta
  • SDF- l ⁇ stromal derived factor- 1 alpha
  • VEGF vascular endothelial growth factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Prostheses (AREA)
  • Materials For Medical Uses (AREA)
  • Polymers & Plastics (AREA)
PCT/US2009/030407 2008-01-08 2009-01-08 Compositions and methods for promoting patency of vascular grafts Ceased WO2009089324A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2010542335A JP2011509156A (ja) 2008-01-08 2009-01-08 血管移植片の開存性を促進するための組成物および方法
US12/811,676 US9855370B2 (en) 2008-01-08 2009-01-08 Compositions and methods for promoting patency of vascular grafts
US15/850,364 US20180193529A1 (en) 2008-01-08 2017-12-21 Compositions and methods for promoting patency of vascular grafts
US17/713,766 US12186455B2 (en) 2008-01-08 2022-04-05 Compositions and methods for promoting patency of vascular grafts

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1040608P 2008-01-08 2008-01-08
US61/010,406 2008-01-08

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/811,676 A-371-Of-International US9855370B2 (en) 2008-01-08 2009-01-08 Compositions and methods for promoting patency of vascular grafts
US15/850,364 Division US20180193529A1 (en) 2008-01-08 2017-12-21 Compositions and methods for promoting patency of vascular grafts

Publications (1)

Publication Number Publication Date
WO2009089324A1 true WO2009089324A1 (en) 2009-07-16

Family

ID=40352092

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/030407 Ceased WO2009089324A1 (en) 2008-01-08 2009-01-08 Compositions and methods for promoting patency of vascular grafts

Country Status (3)

Country Link
US (3) US9855370B2 (enExample)
JP (1) JP2011509156A (enExample)
WO (1) WO2009089324A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140147484A1 (en) * 2011-06-28 2014-05-29 Yale University Cell-Free Tissue Engineered Vascular Grafts
WO2015148775A1 (en) * 2014-03-27 2015-10-01 Board Of Regents, The University Of Texas System Compositions and methods for growing autologous biological tissue
US20200054790A1 (en) * 2017-05-02 2020-02-20 The Johns Hopkins University Implantable vascular grafts
US11541149B2 (en) 2015-12-11 2023-01-03 Research Institute At Nationwide Children's Hospital Systems and methods for optimized patient specific tissue engineering vascular grafts
US12186455B2 (en) 2008-01-08 2025-01-07 Yale University Compositions and methods for promoting patency of vascular grafts

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10195252B2 (en) 2012-08-03 2019-02-05 University of Pittsburgh—of the Commonwealth System of Higher Education Recruitment of mensenchymal cells using controlled release systems
JP2023503256A (ja) * 2019-11-15 2023-01-27 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル 播種されたグラフトを生成するシステムおよび方法
CN119454907A (zh) * 2025-01-09 2025-02-18 浙江大学 Vegf-c156s在制备减轻静脉移植物狭窄的药物中的应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001010421A1 (en) * 1999-08-06 2001-02-15 Board Of Regents, The University Of Texas System Drug releasing biodegradable fiber implant
WO2002102432A1 (en) * 2001-06-15 2002-12-27 Johns Hopkins Singapore Pte Ltd Biofunctional fibers
US20030082148A1 (en) * 2001-10-31 2003-05-01 Florian Ludwig Methods and device compositions for the recruitment of cells to blood contacting surfaces in vivo
WO2005063965A1 (de) * 2003-12-30 2005-07-14 Bionethos Holding Gmbh Verfahren zur regeneration von gewebe
WO2006099332A2 (en) * 2005-03-11 2006-09-21 Wake Forest University Health Sciences Production of tissue engineered digits and limbs
US20080091234A1 (en) * 2006-09-26 2008-04-17 Kladakis Stephanie M Method for modifying a medical implant surface for promoting tissue growth

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5459128A (en) * 1993-11-12 1995-10-17 Dana-Farber Cancer Institute Human monocyte chemoattractant protein-1 (MCP-1) derivatives
US5716394A (en) 1994-04-29 1998-02-10 W. L. Gore & Associates, Inc. Blood contact surfaces using extracellular matrix synthesized in vitro
US6774278B1 (en) 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
US5922554A (en) 1995-10-30 1999-07-13 The Regents Of The University Of California Inhibition of cellular uptake of cholesterol
WO1997028262A1 (en) 1996-02-01 1997-08-07 University Of Florida Lyst1 and lyst2 gene compositions and methods of use
GB9716657D0 (en) * 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
CA2325562A1 (en) 1998-04-03 1999-10-14 Curagen Corporation Lyst protein complexes and lyst interacting proteins
US6984400B2 (en) 1998-07-14 2006-01-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of treating restenosis using bisphosphonate nanoparticles
US7008645B2 (en) 1998-07-14 2006-03-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of inhibiting restenosis using bisphosphonates
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
FR2785812B1 (fr) * 1998-11-16 2002-11-29 Commissariat Energie Atomique Protheses bioactives, notamment a proprietes immunosuppressives, antistenose et antithrombose, et leur fabrication
US7763580B2 (en) 1999-01-05 2010-07-27 University Of Utah Research Foundation Methods for treating conditions associated with the accumulation of excess extracellular matrix
GB9902455D0 (en) * 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
DE60001229T2 (de) 1999-04-09 2003-10-30 Smithkline Beecham Corp., Philadelphia Triarylimidazole
US20020125613A1 (en) 2001-03-08 2002-09-12 Cominsky Kenneth D. Mandrel fabrication for cobond assembly
US6660034B1 (en) * 2001-04-30 2003-12-09 Advanced Cardiovascular Systems, Inc. Stent for increasing blood flow to ischemic tissues and a method of using the same
US20030064965A1 (en) 2001-10-02 2003-04-03 Jacob Richter Method of delivering drugs to a tissue using drug-coated medical devices
NZ532593A (en) 2001-10-25 2007-11-30 Wisconsin Alumni Res Found Vascular stent or graft coated or impregnated with protein tyrosine kinase inhibitors and method of using same
US20040063654A1 (en) 2001-11-02 2004-04-01 Davis Mark E. Methods and compositions for therapeutic use of RNA interference
GB0217786D0 (en) 2002-07-31 2002-09-11 Glaxo Group Ltd Compounds
US20050163821A1 (en) * 2002-08-02 2005-07-28 Hsing-Wen Sung Drug-eluting Biodegradable Stent and Delivery Means
EP1542724A4 (en) * 2002-08-19 2005-10-19 Abgenix Inc ANTIBODIES AGAINST THE MONOCYTE 1 CHIMIOATTRACTIVE PROTEIN (MCP-1) AND USES THEREOF
AU2003290734A1 (en) 2002-11-27 2004-06-23 Eli Lilly And Company Novel compounds as pharmaceutical agents
WO2004073504A2 (en) * 2003-02-20 2004-09-02 Proteon Therapeutics, Llc Methods for the treatment and prevention of diseases of biological conduits
MXPA05009245A (es) 2003-03-11 2005-10-19 Pfizer Prod Inc Nuevos compuestos de pirazina como inhibidores del factor de crecimiento transformante (tgf).
US7314939B2 (en) 2003-06-17 2008-01-01 Millennium Pharmaceuticals, Inc. Compositions and methods for inhibiting TGF-β
WO2005013915A2 (en) 2003-08-08 2005-02-17 The Regents Of The University Of California Novel indications for transforming growth factor-beta regulators
DE502004005857D1 (de) 2003-09-29 2008-02-14 Hemoteq Ag Biokompatible, biostabile beschichtung von medizinischen oberflächen
WO2005049105A2 (en) * 2003-11-10 2005-06-02 Angiotech International Ag Medical implants and anti-scarring agents
US6997989B2 (en) * 2003-12-08 2006-02-14 Boston Scientific Scimed, Inc. Medical implant processing chamber
ATE464855T1 (de) 2004-03-31 2010-05-15 Cook Inc Transplantatmaterial und gefässprothese mit extrazellulärer kollagenmatrix und dessen herstellungsverfahren
US7763065B2 (en) 2004-07-21 2010-07-27 Reva Medical, Inc. Balloon expandable crush-recoverable stent device
JP5144000B2 (ja) 2004-08-25 2013-02-13 太陽化学株式会社 形質転換増殖因子β抑制用組成物
CA2578630A1 (en) 2004-08-31 2006-03-09 Wen-Cherng Lee Pyrimidinylimidazoles as tgf-beta inhibitors
US20060217437A1 (en) 2005-03-17 2006-09-28 Burmester James K TGF-beta modulators and methods for using the same
SG192440A1 (en) * 2005-11-15 2013-08-30 Orbusneich Medical Inc Progenitor endothelial cell capturing with a drug eluting implantable medical device
US20110301098A1 (en) 2006-07-21 2011-12-08 Quax Paul H A Treatment for intimal hyperplasia and related conditions
CN101528752A (zh) 2006-10-16 2009-09-09 辉瑞产品公司 治疗性吡唑基噻吩并吡啶
US7959942B2 (en) 2006-10-20 2011-06-14 Orbusneich Medical, Inc. Bioabsorbable medical device with coating
KR20090122202A (ko) 2007-01-30 2009-11-26 헤모텍 아게 생분해성 혈관 지지체
KR100932688B1 (ko) 2007-07-06 2009-12-21 한국과학기술연구원 인공혈관용 이중막 구조의 튜브형 다공성 스캐폴드 및 그의제조방법
US20090043378A1 (en) * 2007-08-10 2009-02-12 Medtronic Vascular, Inc. Biocompatible Polymer System for Extended Drug Release
US8277832B2 (en) 2007-10-10 2012-10-02 The University Of Kansas Microsphere-based materials with predefined 3D spatial and temporal control of biomaterials, porosity and/or bioactive signals
US7824601B1 (en) 2007-11-14 2010-11-02 Abbott Cardiovascular Systems Inc. Process of making a tubular implantable medical device
WO2009089324A1 (en) 2008-01-08 2009-07-16 Yale University Compositions and methods for promoting patency of vascular grafts
US20100092534A1 (en) * 2008-10-10 2010-04-15 Medtronic Vascular, Inc. Combination Local Delivery Using a Stent
US20100129414A1 (en) 2008-11-24 2010-05-27 Medtronic Vascular, Inc. Bioactive Agent Delivery Using Liposomes in Conjunction With Stent Deployment
AU2010353739B2 (en) 2010-05-17 2014-03-27 Pall Corporation System for seeding cells onto three dimensional scaffolds
RU2440128C1 (ru) 2010-05-17 2012-01-20 Государственное образовательное учреждение дополнительного профессионального образования "Санкт-Петербургская медицинская академия последипломного образования Федерального агентства по здравоохранению и социальному развитию" (ГОУ ДПО СПбМАПО Росздрава) Способ комплексной патогенетической терапии острых форм вирусного гепатита в и микст-гепатитов (в+с, в+d, в+с+d)
US9090863B2 (en) 2010-05-17 2015-07-28 Pall Corporation System for seeding cells onto three dimensional scaffolds
US20130013083A1 (en) 2011-01-06 2013-01-10 Humacyte Tissue-Engineered Constructs
US10227568B2 (en) 2011-03-22 2019-03-12 Nanofiber Solutions, Llc Fiber scaffolds for use in esophageal prostheses
WO2013003157A1 (en) 2011-06-28 2013-01-03 Yale University Cell-free tissued engineered vascular grafts
EP2971318B1 (en) 2013-03-15 2021-07-21 Nanofiber Solutions, LLC Biocompatible fiber textiles for implantation
WO2014197790A1 (en) 2013-06-06 2014-12-11 University Of Maryland, College Park Compositions and methods for making biodegradable structures
WO2017100782A1 (en) 2015-12-11 2017-06-15 Research Institute At Nationwide Children's Hospital Systems and methods for optimized patent specific tissue engineering vascular grafts

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001010421A1 (en) * 1999-08-06 2001-02-15 Board Of Regents, The University Of Texas System Drug releasing biodegradable fiber implant
WO2002102432A1 (en) * 2001-06-15 2002-12-27 Johns Hopkins Singapore Pte Ltd Biofunctional fibers
US20050058692A1 (en) * 2001-06-15 2005-03-17 Mao Hai-Quan Biofunctional fibers
US20030082148A1 (en) * 2001-10-31 2003-05-01 Florian Ludwig Methods and device compositions for the recruitment of cells to blood contacting surfaces in vivo
WO2005063965A1 (de) * 2003-12-30 2005-07-14 Bionethos Holding Gmbh Verfahren zur regeneration von gewebe
WO2006099332A2 (en) * 2005-03-11 2006-09-21 Wake Forest University Health Sciences Production of tissue engineered digits and limbs
US20080091234A1 (en) * 2006-09-26 2008-04-17 Kladakis Stephanie M Method for modifying a medical implant surface for promoting tissue growth

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BRENNAN MATTHEW P ET AL: "Tissue-engineered vascular grafts demonstrate evidence of growth and development when implanted in a juvenile animal model.", ANNALS OF SURGERY SEP 2008, vol. 248, no. 3, September 2008 (2008-09-01), pages 370 - 377, XP009113975, ISSN: 1528-1140 *
ROH ET AL: "Construction of an autologous tissue-engineered venous conduit from bone marrow-derived vascular cells: optimization of cell harvest and seeding techniques", JOURNAL OF PEDIATRIC SURGERY, W. B. SAUNDERS COMPANY, US, vol. 42, no. 1, 17 January 2007 (2007-01-17), pages 198 - 202, XP005821098, ISSN: 0022-3468 *
SAITO N ET AL: "A biodegradable polymer as a cytokine delivery system for inducing bone formation", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 19, no. 4, 1 April 2001 (2001-04-01), pages 332 - 335, XP002393770, ISSN: 1087-0156 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12186455B2 (en) 2008-01-08 2025-01-07 Yale University Compositions and methods for promoting patency of vascular grafts
US20140147484A1 (en) * 2011-06-28 2014-05-29 Yale University Cell-Free Tissue Engineered Vascular Grafts
US9326951B2 (en) * 2011-06-28 2016-05-03 Yale University Cell-free tissue engineered vascular grafts
US20160271152A1 (en) * 2011-06-28 2016-09-22 Yale University Cell-free tissued engineered vascular grafts
US10300082B2 (en) * 2011-06-28 2019-05-28 Yale University Cell-free tissued engineered vascular grafts
WO2015148775A1 (en) * 2014-03-27 2015-10-01 Board Of Regents, The University Of Texas System Compositions and methods for growing autologous biological tissue
US11541149B2 (en) 2015-12-11 2023-01-03 Research Institute At Nationwide Children's Hospital Systems and methods for optimized patient specific tissue engineering vascular grafts
US12115282B2 (en) 2015-12-11 2024-10-15 Research Institute At Nationwide Children's Hospital Systems and methods for optimized patient specific tissue engineering vascular grafts
US20200054790A1 (en) * 2017-05-02 2020-02-20 The Johns Hopkins University Implantable vascular grafts

Also Published As

Publication number Publication date
US20220226542A1 (en) 2022-07-21
US9855370B2 (en) 2018-01-02
US20100303889A1 (en) 2010-12-02
US20180193529A1 (en) 2018-07-12
US12186455B2 (en) 2025-01-07
JP2011509156A (ja) 2011-03-24

Similar Documents

Publication Publication Date Title
US12186455B2 (en) Compositions and methods for promoting patency of vascular grafts
Mrówczyński et al. Porcine carotid artery replacement with biodegradable electrospun poly-e-caprolactone vascular prosthesis
Guo et al. A simply prepared small-diameter artificial blood vessel that promotes in situ endothelialization
US10582996B2 (en) Biodegradable vascular grafts
EP1988847B1 (en) Functionalizing implantable devices with a poly (diol-co-citrate) polymer
Rolfe et al. The fibrotic response to implanted biomaterials: implications for tissue engineering
JP6118905B2 (ja) 心臓修復パッチの新しいスキャフォールド
Liu et al. Development of a decellularized human amniotic membrane-based electrospun vascular graft capable of rapid remodeling for small-diameter vascular applications
JP2008518666A (ja) 生物活性創傷包帯および移植可能な装置ならびに使用法
JP6972152B2 (ja) 心血管移植片
CN113244462B (zh) 一种防止支架内再狭窄的药物涂层血管支架及制备方法
US20170333603A1 (en) Tissue regeneration membrane
AU2012304662B2 (en) Surgical sutures and methods of making and using same
Yang et al. VEGF combined with DAPT promotes tissue regeneration and remodeling in vascular grafts
Snyder et al. Blood biocompatibility assessment of an intravenous gas exchange device
JP2023503256A (ja) 播種されたグラフトを生成するシステムおよび方法
CA2483096A1 (en) Medical device
Li et al. Nano-biological mesh constructed by astragaloside-IV-induced bone marrow mesenchymal stem cells on PLGA-NPs-SIS can be used for abdominal wall reconstruction
Vu Biomaterial-Mediated Immunomodulation Via The Implantation of Drug-Eluting Vascular Grafts
Zhang Engineering an Immunomodulatory Fiber-Reinforced Hydrogel Composite Vascular Graft to Promote Vascular Regeneration
김강민 Evaluation of biocompatibility of intra-arterial poly-L-lactic acid stent by tantalum ion implantation
van Almen PhD et al. Early in-situ cellularization of a supramolecular vascular graft is modified by synthetic stromal cell-derived factor-1α derived peptides
Goins Engineering a Biomimetic Scaffold for Small Diameter Blood Vessel Tissue Engineering
JP2015112262A (ja) 組織修復及び／又は再生促進材
Malhotra Improving Matters of the Heart: The Use of Select Pharmaceutical Polymers in Cardiovascular Intervention

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09701423

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 12811676

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2010542335

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09701423

Country of ref document: EP

Kind code of ref document: A1